Although SGLT2 inhibitors could be safely prescribed to diabetic patients with COVID-19, randomized trials have shown that treatment with an SGLT2 inhibitor was not associated with improved clinical outcomes [11]. This evidence concerns the gene SLC5A2 and COVID-19.